Literature DB >> 15145699

Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle.

Christopher J Fowler1, Gunnar Tiger, Alessia Ligresti, María L López-Rodríguez, Vincenzo Di Marzo.   

Abstract

There is considerable debate at present as to whether the uptake of anandamide (AEA) into cells is by a facilitated transport process or by passive diffusion driven by fatty acid amide hydrolase (FAAH). The possibility that both processes occur, but to different extents depending upon the cell type used, has been difficult to investigate pharmacologically since available compounds show little selectivity between inhibition of AEA uptake and inhibition of FAAH. Recently, three compounds, UCM707 [N-(Fur-3-ylmethyl)arachidonamide], OMDM-1 and OMDM-2 [the 1'-(S)- and 1'-(R)-enantiomers of the 1'-4-hydroxybenzoyl analogue of oleoylethanolamide], selective for the uptake process, have been described and we have used these compounds, together with AM404 [(N-(4-hydroxyphenyl) arachidonoyl amide)] and VDM11 [(5Z,8Z,11Z,14Z)-N-(4-Hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide]), with the initial aim of determining which mechanism of uptake predominates in C6 glioma and RBL-2H3 cells. AM404 and VDM11 were both found to decrease the uptake of 2 microM AEA into cells (IC50 values 6-11 microM), but they also inhibited rat brain FAAH (IC50 values 1-6 microM). However, when using a different FAAH assay protocol, VDM11 was a much less potent FAAH inhibitor (IC50>50 microM) regardless of the cell type and animal species used. In contrast, we confirmed that UCM707, OMDM-1 and OMDM-2 were weak inhibitors of FAAH (IC50 values >50 microM) under all conditions used. However, their potency as inhibitors of AEA cellular accumulation appears to be largely dependent on the cell type and assay conditions used. In particular, the potency of UCM707 (IC50 value > or =25 microM) was considerably lower than the submicromolar potency previously reported for U937 cells. It is concluded that the cause/effect relationship between AEA uptake and hydrolysis cannot be investigated uniquely by using supposedly selective inhibitors of each process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15145699     DOI: 10.1016/j.ejphar.2004.03.048

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  38 in total

1.  Pitfalls and solutions in assaying anandamide transport in cells.

Authors:  Sergio Oddi; Filomena Fezza; Giuseppina Catanzaro; Chiara De Simone; Mariangela Pucci; Daniele Piomelli; Alessandro Finazzi-Agrò; Mauro Maccarrone
Journal:  J Lipid Res       Date:  2010-05-06       Impact factor: 5.922

Review 2.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

3.  Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.

Authors:  Amy K Dickason-Chesterfield; Stephanie R Kidd; Steven A Moore; John M Schaus; Bin Liu; George G Nomikos; Christian C Felder
Journal:  Cell Mol Neurobiol       Date:  2006-05-31       Impact factor: 5.046

Review 4.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

5.  Evidence for bidirectional endocannabinoid transport across cell membranes.

Authors:  Andrea Chicca; Janine Marazzi; Simon Nicolussi; Jürg Gertsch
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

Review 6.  "Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control.

Authors:  Fabiana Piscitelli; Vincenzo Di Marzo
Journal:  ACS Chem Neurosci       Date:  2012-02-27       Impact factor: 4.418

7.  A role for the anandamide membrane transporter in TRPV1-mediated neurosecretion from trigeminal sensory neurons.

Authors:  Theodore J Price; Amol M Patwardhan; Christopher M Flores; Kenneth M Hargreaves
Journal:  Neuropharmacology       Date:  2005-04-01       Impact factor: 5.250

Review 8.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Mol Neurobiol       Date:  2007-06-26       Impact factor: 5.590

9.  Exploiting nanotechnologies and TRPV1 channels to investigate the putative anandamide membrane transporter.

Authors:  Alessia Ligresti; Luciano De Petrocellis; Dolores Hernán Pérez de la Ossa; Rosario Aberturas; Luigia Cristino; Aniello Schiano Moriello; Andrea Finizio; M Esther Gil; Ana-Isabel Torres; Jesús Molpeceres; Vincenzo Di Marzo
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

10.  The insertion and transport of anandamide in synthetic lipid membranes are both cholesterol-dependent.

Authors:  Eric Di Pasquale; Henri Chahinian; Patrick Sanchez; Jacques Fantini
Journal:  PLoS One       Date:  2009-03-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.